IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.71
−3.90%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$36.35
From 52W high−18.29%
Volume1.13M
Market cap$3.35B
P/E (TTM)—
P/S (TTM)14.3x
Div yield—
Key dataOct 23, 2026
Open
$36.35
From 52W high
−18.29%
Volume
1.13M
Market cap
$3.35B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.0x
P/E (TTM)
—
RSI (14)
44.5
MomentumView details →
1D Return
−3.90%
YTD Return
+1.66%
SummaryUpdated Jun 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.
Similar companies
Latest newsMore news →
IDEAYA Biosciences, Inc. said it is targeting two Phase 3 registrational trials of IDE849 in extensive-stage small cell lung cancer and neuroendocrine carcinomas following successful Type C meetings with the U.S. FDA.1d agoIDEAYA Biosciences, Inc. reported updated Phase 1 results for IDE849 in relapsed small cell lung cancer and neuroendocrine carcinomas, including median overall survival of 17.4 months in second-line SCLC and 14.7 months in second-line or later SCLC.1d agoIDEAYA Biosciences promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.26d ago